| Lake Whatcom Residential & Treatment Center | |
|
3600 Meridian St Bellingham WA 98225-1756 | |
| (360) 676-6000 | |
| (360) 676-6006 |
| Full Name | Lake Whatcom Residential & Treatment Center |
|---|---|
| Speciality | Community/Behavioral Health |
| Location | 3600 Meridian St, Bellingham, Washington |
| Authorized Official Name and Position | Stephanie Ann Zapien (FINANCE/IT DIRECTOR) |
| Authorized Official Contact | 3606766000 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Lake Whatcom Residential & Treatment Center 3600 Meridian St Bellingham WA 98225-1756 Ph: (360) 676-6000 | Lake Whatcom Residential & Treatment Center 3600 Meridian St Bellingham WA 98225-1756 Ph: (360) 676-6000 |
| NPI Number | 1043281736 |
|---|---|
| Provider Enumeration Date | 01/30/2006 |
| Last Update Date | 06/02/2023 |
| Certification Date | 06/02/2023 |
| Medicare PECOS PAC ID | 8820068661 |
|---|---|
| Medicare Enrollment ID | O20040728001462 |
News Archive
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.
Ortivus is now implementing its strategy to streamline its core operations into a clear focus on advanced mobile and clinical decision support for modern medical care. Consequently its North American subsidiaries, which provide administrative systems primarily for ambulance services, have been sold to an American company - TriTech Software Systems.
From Promise to Practice is the title and the main message of the second annual Individualizing Medicine Conference at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more than 40 states and several countries will be arriving in Minnesota to hear and learn about the latest developments and research in genomic research and how to move these discoveries into the medical practice.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
There is renewed hope for treatment of a rare genetic condition that causes rapidly accelerated aging and leads to an average life expectancy of 13 years.
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043281736 | NPI | - | NPPES |
| 7043615 | Medicaid | WA |
| Provider Name | Dennis W Gaither |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1730123084 PECOS PAC ID: 1658326012 Enrollment ID: I20050317001054 |
News Archive
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.
Ortivus is now implementing its strategy to streamline its core operations into a clear focus on advanced mobile and clinical decision support for modern medical care. Consequently its North American subsidiaries, which provide administrative systems primarily for ambulance services, have been sold to an American company - TriTech Software Systems.
From Promise to Practice is the title and the main message of the second annual Individualizing Medicine Conference at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more than 40 states and several countries will be arriving in Minnesota to hear and learn about the latest developments and research in genomic research and how to move these discoveries into the medical practice.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
There is renewed hope for treatment of a rare genetic condition that causes rapidly accelerated aging and leads to an average life expectancy of 13 years.
› Verified 4 days ago
| Provider Name | Sara J Wells |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497703359 PECOS PAC ID: 7012993405 Enrollment ID: I20060713000312 |
News Archive
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.
Ortivus is now implementing its strategy to streamline its core operations into a clear focus on advanced mobile and clinical decision support for modern medical care. Consequently its North American subsidiaries, which provide administrative systems primarily for ambulance services, have been sold to an American company - TriTech Software Systems.
From Promise to Practice is the title and the main message of the second annual Individualizing Medicine Conference at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more than 40 states and several countries will be arriving in Minnesota to hear and learn about the latest developments and research in genomic research and how to move these discoveries into the medical practice.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
There is renewed hope for treatment of a rare genetic condition that causes rapidly accelerated aging and leads to an average life expectancy of 13 years.
› Verified 4 days ago
| Provider Name | Angela M Belcaster |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528391794 PECOS PAC ID: 5799823951 Enrollment ID: I20091109000071 |
News Archive
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.
Ortivus is now implementing its strategy to streamline its core operations into a clear focus on advanced mobile and clinical decision support for modern medical care. Consequently its North American subsidiaries, which provide administrative systems primarily for ambulance services, have been sold to an American company - TriTech Software Systems.
From Promise to Practice is the title and the main message of the second annual Individualizing Medicine Conference at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more than 40 states and several countries will be arriving in Minnesota to hear and learn about the latest developments and research in genomic research and how to move these discoveries into the medical practice.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
There is renewed hope for treatment of a rare genetic condition that causes rapidly accelerated aging and leads to an average life expectancy of 13 years.
› Verified 4 days ago
| Provider Name | Rita Palisaityte |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1407929383 PECOS PAC ID: 2860709995 Enrollment ID: I20150922001032 |
News Archive
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.
Ortivus is now implementing its strategy to streamline its core operations into a clear focus on advanced mobile and clinical decision support for modern medical care. Consequently its North American subsidiaries, which provide administrative systems primarily for ambulance services, have been sold to an American company - TriTech Software Systems.
From Promise to Practice is the title and the main message of the second annual Individualizing Medicine Conference at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more than 40 states and several countries will be arriving in Minnesota to hear and learn about the latest developments and research in genomic research and how to move these discoveries into the medical practice.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
There is renewed hope for treatment of a rare genetic condition that causes rapidly accelerated aging and leads to an average life expectancy of 13 years.
› Verified 4 days ago
| Provider Name | Jesse C Moline |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639783079 PECOS PAC ID: 3274999651 Enrollment ID: I20230510002945 |
News Archive
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.
Ortivus is now implementing its strategy to streamline its core operations into a clear focus on advanced mobile and clinical decision support for modern medical care. Consequently its North American subsidiaries, which provide administrative systems primarily for ambulance services, have been sold to an American company - TriTech Software Systems.
From Promise to Practice is the title and the main message of the second annual Individualizing Medicine Conference at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more than 40 states and several countries will be arriving in Minnesota to hear and learn about the latest developments and research in genomic research and how to move these discoveries into the medical practice.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
There is renewed hope for treatment of a rare genetic condition that causes rapidly accelerated aging and leads to an average life expectancy of 13 years.
› Verified 4 days ago
News Archive
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed glioblastoma multiforme (GBM) in its randomized, placebo-controlled phase II trial.
Ortivus is now implementing its strategy to streamline its core operations into a clear focus on advanced mobile and clinical decision support for modern medical care. Consequently its North American subsidiaries, which provide administrative systems primarily for ambulance services, have been sold to an American company - TriTech Software Systems.
From Promise to Practice is the title and the main message of the second annual Individualizing Medicine Conference at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more than 40 states and several countries will be arriving in Minnesota to hear and learn about the latest developments and research in genomic research and how to move these discoveries into the medical practice.
Gilead Sciences, Inc. announced today that it has refiled a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the single-tablet regimen of Truvada® (emtricitabine and tenofovir disoproxil fumarate) and Tibotec Pharmaceuticals' investigational non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine hydrochloride) for HIV-1 infection in adults.
There is renewed hope for treatment of a rare genetic condition that causes rapidly accelerated aging and leads to an average life expectancy of 13 years.
› Verified 4 days ago
Northwest Medical Psychology Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3120 Squalicum Pkwy, Suite 2, Bellingham, WA 98225 Phone: 360-734-4046 Fax: 360-734-6727 | |
Whatcom Counseling & Psychiatric Clinic Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3645 E Mcleod Rd, Bellingham, WA 98226 Phone: 360-676-2220 Fax: 360-676-7750 | |
Rehabilitation Psychology Services P S Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 801 Samish Way, Bellingham, WA 98229 Phone: 360-255-2505 Fax: 360-255-2504 | |
Center For The Psychology Of Women Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2623 Orleans St, Bellingham, WA 98226 Phone: 323-491-7737 | |
Aaron James Williams Licsw Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3031 Orleans St Ste 101, Bellingham, WA 98226 Phone: 831-204-8295 | |
Mobile Mama Strategies, Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 214 N Commercial St Ste 102, Bellingham, WA 98225 Phone: 360-393-5114 Fax: 360-733-1928 |